Qilu Pharmaceutical (Hainan) Co., Ltd.
Quick facts
Marketed products
Phase 3 pipeline
- QLG2071 · Diabetes
QLG2071 is a small molecule drug that targets the SGLT2 receptor. - QLG2198 · Diabetes
QLG2198 is a small molecule drug that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Qilu Pharmaceutical (Hainan) Co., Ltd. portfolio CI brief
- Qilu Pharmaceutical (Hainan) Co., Ltd. pipeline updates RSS
Frequently asked questions about Qilu Pharmaceutical (Hainan) Co., Ltd.
What are Qilu Pharmaceutical (Hainan) Co., Ltd.'s marketed drugs?
Top marketed products include Aprepitant Injection.
What is Qilu Pharmaceutical (Hainan) Co., Ltd.'s pipeline?
Qilu Pharmaceutical (Hainan) Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include QLG2071, QLG2198.
Related
- Aprepitant Injection
- Sector hub: All tracked pharma companies